Pediatric Asthma Management

Introduction to Asthma Treatment

The American Academy of Pediatrics recommends low-dose inhaled corticosteroids (ICS) as the best and most effective first-line inhaler therapy for children with persistent asthma at all ages, with superior outcomes compared to all other long-term controller medications 1, 2

For children 5 years and older, the American Academy of Allergy, Asthma, and Immunology recommends low-dose inhaled corticosteroids as the preferred therapy for mild persistent asthma, delivered via metered-dose inhaler (MDI) with spacer or dry powder inhaler (DPI) 1, 3
For children younger than 5 years, the American Academy of Pediatrics recommends low-dose ICS as the preferred first-line therapy, delivered via nebulizer, DPI, or MDI with valved holding chamber (with or without face mask) 1, 2

Strong evidence from the Journal of Allergy and Clinical Immunology establishes ICS improve prebronchodilator FEV₁, reduce hyperresponsiveness, improve symptom scores, reduce oral corticosteroid courses, and decrease urgent care visits/hospitalizations compared to as-needed beta₂-agonists 1, 3

The American Academy of Allergy, Asthma, and Immunology lists cromolyn, leukotriene receptor antagonists (montelukast), nedocromil, and sustained-release theophylline as alternative controller options when ICS cannot be used 2, 3

The American Academy of Pediatrics states that low-to-medium dose ICS have no clinically significant effects on hypothalamic-pituitary-adrenal axis function in most children, and growth velocity reduction is small and nonprogressive 2, 4
The American Academy of Allergy, Asthma, and Immunology recommends titrating to the lowest effective dose needed to maintain control and minimizing systemic effects by mouth rinsing after each treatment 2, 4

The American Academy of Pediatrics recommends that long-acting beta₂-agonists (LABAs) should NEVER be used as monotherapy and only in combination with ICS for moderate-to-severe asthma not controlled on low-dose ICS alone 2

The American Academy of Pediatrics recommends initiating daily ICS when symptoms require treatment >2 times per week, or severe exacerbations require beta-agonist more frequently than every 4 hours over 24 hours 2
The American Academy of Allergy, Asthma, and Immunology recommends evaluating response within 4-6 weeks of initiating therapy and stopping treatment if no clear beneficial effect is obvious within 4-6 weeks and reconsidering diagnosis or alternative therapies 1, 2